In summary, we identified RIPK2 as an actionable drug target for inhibiting PC metastasis, operating largely via the noncanonical RIPK2/MKK7(/JNK)/c-Myc signaling pathway discovered in this study. Here, RIPK2 is linked to pachyonychia congenita.